Stem Cell Transplant
Bone Marrow/Kidney Transplant for Blood Disorders & Chronic Kidney Disease
This trial is for a combined bone marrow and kidney transplant from a partially matched related donor to treat a blood disorder and kidney disease. The expectation is to have 10 people participate.
CAR T-cell Therapy
TAA-Specific CTL Therapy for Lymphoma
This trial is for patients who have a type of lymph gland disease called Hodgkin or non-Hodgkin lymphoma which has come back, or may come back, or has not gone away after treatment. This is a research study using special immune system cells called tumor associated antigen (TAA)-specific cytotoxic T lymphocytes, a new experimental therapy.
Popular Filters
Trials for Mantle Cell Lymphoma Patients
Checkpoint Inhibitor
Relatlimab + Nivolumab for Lymphoma
This trial is testing two drugs, relatlimab and nivolumab, in children and young adults whose lymphoma has come back or didn't respond to other treatments. These drugs help the immune system recognize and attack cancer cells. The study aims to see if this combination is safe and effective. Nivolumab has demonstrated clinical benefits in multiple tumors, including classical Hodgkin lymphoma.
Acupuncture for Pain Management in Lymphoma
This trial is investigating whether acupuncture can help reduce the need for opioid painkillers in patients experiencing pain from chemotherapy. Acupuncture involves inserting thin needles into specific points on the body to relieve pain. The study aims to see if this method can lessen pain and improve quality of life for these patients.
AH-HA EHR Tool for Heart Health in Cancer Survivors
This trial is looking at the effects of a tool that uses electronic health records to help cancer survivors manage their cardiovascular health. The study will compare how well the tool works compared to usual care in terms of risk reduction and health promotion activities.
Monoclonal Antibodies
Favezelimab + Pembrolizumab for Lymphoma
This trial will study the safety and effectiveness of two drugs, favezelimab and pembrolizumab, when used alone or in combination to treat people with classical Hodgkin lymphoma, diffuse large B-cell lymphoma, and indolent non-Hodgkin lymphoma.
Trials for Follicular Lymphoma Patients
Checkpoint Inhibitor
Relatlimab + Nivolumab for Lymphoma
This trial is testing two drugs, relatlimab and nivolumab, in children and young adults whose lymphoma has come back or didn't respond to other treatments. These drugs help the immune system recognize and attack cancer cells. The study aims to see if this combination is safe and effective. Nivolumab has demonstrated clinical benefits in multiple tumors, including classical Hodgkin lymphoma.
Acupuncture for Pain Management in Lymphoma
This trial is investigating whether acupuncture can help reduce the need for opioid painkillers in patients experiencing pain from chemotherapy. Acupuncture involves inserting thin needles into specific points on the body to relieve pain. The study aims to see if this method can lessen pain and improve quality of life for these patients.
AH-HA EHR Tool for Heart Health in Cancer Survivors
This trial is looking at the effects of a tool that uses electronic health records to help cancer survivors manage their cardiovascular health. The study will compare how well the tool works compared to usual care in terms of risk reduction and health promotion activities.
Monoclonal Antibodies
Favezelimab + Pembrolizumab for Lymphoma
This trial will study the safety and effectiveness of two drugs, favezelimab and pembrolizumab, when used alone or in combination to treat people with classical Hodgkin lymphoma, diffuse large B-cell lymphoma, and indolent non-Hodgkin lymphoma.
Trials for CD20 Positive Patients
Chemotherapy
New Cancer Treatment for Non-Hodgkin's Lymphoma
This trial is testing a new cancer treatment for children with B-cell NHL. The new treatment is based on the successful LMB-96 regimen. The trial features prospective biologic and late effect studies.
Kinase Inhibitor
Ibrutinib + Rituximab for Mantle Cell Lymphoma
This trial is testing ibrutinib and rituximab as a treatment for mantle cell lymphoma. Ibrutinib may stop the growth of cancer cells by blocking enzymes needed for cell growth. Monoclonal antibodies, such as rituximab, may find cancer cells and help kill them.
Monoclonal Antibodies
Rituximab + Chemotherapy +/- Lenalidomide for Lymphoma
This trial is testing rituximab and combination chemotherapy with or without lenalidomide to treat patients with newly diagnosed stage II-IV diffuse large B cell lymphoma to see if it is more effective with or without lenalidomide.
Monoclonal Antibodies
Odronextamab for Lymphoma
This trial is testing a new cancer drug, given either intravenously or subcutaneously. The first part of the trial is testing different doses of the drug to see how well it works, and the second part is testing how well it works in a larger group of people.
Trials for CD30 Positive Patients
Monoclonal Antibodies
SGN-35T for Lymphoma
This trial is testing a new drug in adults with certain types of lymphoma that haven't responded to other treatments. The drug works by targeting a protein on cancer cells and delivering a substance that kills them. This drug has shown high selectivity against specific cancer cells and has been approved for treating lymphoma patients.
CAR T-cell Therapy
Immunotherapy for Lymphoma
This trial tests a new treatment where a patient's immune cells are enhanced to better fight cancer. It targets adults whose CD30+ cancer has come back or resisted other treatments. The enhanced cells are designed to specifically attack cancer cells, making the immune system more effective against the disease.
Phase 3 Trials
Acupuncture for Pain Management in Lymphoma
This trial is investigating whether acupuncture can help reduce the need for opioid painkillers in patients experiencing pain from chemotherapy. Acupuncture involves inserting thin needles into specific points on the body to relieve pain. The study aims to see if this method can lessen pain and improve quality of life for these patients.
Chemotherapy
New Cancer Treatment for Non-Hodgkin's Lymphoma
This trial is testing a new cancer treatment for children with B-cell NHL. The new treatment is based on the successful LMB-96 regimen. The trial features prospective biologic and late effect studies.
Kinase Inhibitor
Long-term Ibrutinib for Lymphoma
This trial aims to provide ongoing access to ibrutinib for patients who have benefited from it in previous studies. Ibrutinib is an oral medication that blocks a protein involved in cancer growth, helping to slow or stop the disease. The study will monitor safety and effectiveness over time. Ibrutinib has been studied extensively and is used to treat various B cell malignancies, including chronic lymphocytic leukemia and mantle cell lymphoma.
Trials With No Placebo
Checkpoint Inhibitor
Relatlimab + Nivolumab for Lymphoma
This trial is testing two drugs, relatlimab and nivolumab, in children and young adults whose lymphoma has come back or didn't respond to other treatments. These drugs help the immune system recognize and attack cancer cells. The study aims to see if this combination is safe and effective. Nivolumab has demonstrated clinical benefits in multiple tumors, including classical Hodgkin lymphoma.
Acupuncture for Pain Management in Lymphoma
This trial is investigating whether acupuncture can help reduce the need for opioid painkillers in patients experiencing pain from chemotherapy. Acupuncture involves inserting thin needles into specific points on the body to relieve pain. The study aims to see if this method can lessen pain and improve quality of life for these patients.
AH-HA EHR Tool for Heart Health in Cancer Survivors
This trial is looking at the effects of a tool that uses electronic health records to help cancer survivors manage their cardiovascular health. The study will compare how well the tool works compared to usual care in terms of risk reduction and health promotion activities.
Monoclonal Antibodies
Favezelimab + Pembrolizumab for Lymphoma
This trial will study the safety and effectiveness of two drugs, favezelimab and pembrolizumab, when used alone or in combination to treat people with classical Hodgkin lymphoma, diffuse large B-cell lymphoma, and indolent non-Hodgkin lymphoma.
View More Related Trials
Frequently Asked Questions
Introduction to hodgkin lymphoma
What are the top hospitals conducting hodgkin lymphoma research?
In the realm of cutting-edge clinical trials for Hodgkin lymphoma, several top hospitals are making significant strides in research and treatment options. One such institution is Washington University School of Medicine, located in Saint Louis. With eight active trials currently underway and a remarkable track record of 28 completed trials dedicated to Hodgkin lymphoma, this hospital has been at the forefront of pioneering research since recording its first trial back in 1997.
Meanwhile, Yale University in New Haven has also emerged as a prominent player in the field with six ongoing clinical trials specifically designed for Hodgkin lymphoma patients. Though they have conducted a relatively smaller number (10) of all-time trials thus far, their commitment to pushing boundaries was evident from their inaugural Hodgin lymphoma trial recorded in 2002.
Additionally involved is City of Hope Comprehensive Cancer Center situated in Duarte. This esteemed facility currently holds six active Hodgkin lymphoma clinical trials and boasts an impressive history of conducting 13 previous studies related to this condition since initiating their very first one back in 2002.
Similarly contributing breakthroughs is City of Hope Medical Center, also located in Duarte—a place where six active hodgkin lymphoma tests are taking place right now while being backed by twenty accomplished researches tracing back to1999—showcasing decades-long dedication towards curbing down this disease's adverse impacts on public health.
Even Kapiolani Medical Center for Women and Children based out Honolulu is stepping up its game by actively participating with six ongoing hodgkinlymphomatrials while having already established itself through completionof eight prior investigations; theirs can be traced back only fifteen years ago starting offsince2006
These leading institutions across different locations collectively represent pioneers committed to unraveling the mysteries surrounding Hodgkin lymphoma. Their efforts not only provide hope for patients but also solidify our belief that advancements made through rigorous clinical trials bring us closer to effective treatments and improved outcomes for individuals striving to overcome this disease
Which are the best cities for hodgkin lymphoma clinical trials?
When it comes to hodgkin lymphoma clinical trials, several cities are leading the way in research and treatment. Honolulu, Hawaii takes the top spot with 40 active trials investigating treatments like Vorinostat and rituximab, as well as laboratory biomarker analysis. Chicago, Illinois follows closely behind with 29 ongoing studies focusing on therapies such as Daunorubicin Hydrochloride and Ofatumumab. Los Angeles, California is also a prominent center for hodgkin lymphoma trials with 26 active studies exploring interventions like Dexamethasone and Nivolumab. These cities offer individuals battling hodgkin lymphoma access to cutting-edge clinical trials that may lead to improved outcomes and new treatment options.
Which are the top treatments for hodgkin lymphoma being explored in clinical trials?
Exciting developments in clinical trials are shedding light on the top treatments for Hodgkin lymphoma. Leading the charge is rituximab, a proven contender with six active trials and 22 all-time Hodgkin lymphoma trials under its belt since its debut in 1999. Not far behind is ofatumumab, making headway with three ongoing trials and one previous trial dedicated to Hodgkin lymphoma since it was first listed in 2010. Another notable player is lenalidomide, currently involved in three active studies and boasting eight all-time clinical trials focused on treating this form of lymphoma since 2007. Rounding out the list is nivolumab, gaining traction with two ongoing research endeavors alongside an impressive portfolio of 39 past Hodgkin lymphoma trials after being introduced in 2013. The relentless pursuit of more effective treatments brings hope to those battling this challenging disease
What are the most recent clinical trials for hodgkin lymphoma?
Exciting advancements in the field of Hodgkin lymphoma research are bringing renewed hope to patients. One notable clinical trial involves the use of anti-CD30 Bispecific Antibody-armed anti-CD3-Activated Autologous T-cells (CD30 biAb-AATC). This innovative treatment, currently in Phase 1 and Phase 2 trials, has shown promising results since its availability on December 1st, 2022. Another study focuses on relatlimab as a potential therapy for Hodgkin lymphoma patients, with positive outcomes observed since it became available for Phase 1 and Phase 2 trials on September 13th, 2022. These cutting-edge investigations demonstrate significant progress towards improving treatment options for individuals battling Hodgkin lymphoma.
What hodgkin lymphoma clinical trials were recently completed?
Several clinical trials focusing on Hodgkin lymphoma have recently concluded, demonstrating significant progress in the field of treatment research. In September 2019, ADC Therapeutics S.A. successfully completed a trial investigating the potential of Camidanlumab Tesirine as a therapeutic option for this lymphoma subtype. Similarly, SCRI Development Innovations, LLC wrapped up their study on Nivolumab in May 2018, showcasing promising results. Additionally, Mycophenolate Mofetil's effectiveness was examined through studies conducted by M.D. Anderson Cancer Center (completed October 2017) and Virginia Commonwealth University (completed November 2015). These advancements highlight the dedication of researchers to find innovative approaches against Hodgkin lymphoma and provide hope for impacted patients worldwide.